Veterinary Medicines

FLIMABEND 100 MG/G SUSPENSION FOR USE IN DRINKING WATER FOR CHICKENS AND PIGS

Authorised
  • Flubendazole
Download as PDF

Product identification

Medicine name:
FLIMABEND 100 MG/G SUSPENSION FOR USE IN DRINKING WATER FOR CHICKENS AND PIGS
FLIMABEND 100 mg/g SUSPENSION PARA ADMINISTRACION EN AGUA DE BEBIDA PARA POLLOS Y PORCINO
Active substance:
  • Flubendazole
Target species:
  • Chicken (broiler)
  • Pig
  • Chicken
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Flubendazole
    100.00
    milligram(s)
    /
    1.00
    gram(s)
Pharmaceutical form:
  • Oral suspension
Withdrawal period by route of administration:
  • Oral use
    • Chicken (broiler)
      • Meat and offal
        2
        day
    • Pig
      • Meat and offal
        3
        day
      • Meat and offal
        4
        day
    • Chicken
      • Eggs
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP52AC12
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Spain
Package description:
  • Cardboard box containing 2 sachets of 20 g suspension for use in drinking water
  • Cardboard box containing 6 containers of 750 g suspension for use in drinking water
  • Cardboard box containing 4 containers of 750 g suspension for use in drinking water
  • Cardboard box containing 25 sachets of 100 g suspension for use in drinking water
  • Cardboard box containing 5 sachets of 100 g suspension for use in drinking water
  • Cardboard box containing 1 sachet of 100 g suspension for use in drinking water
  • Cardboard box containing 24 sachets of 50 g suspension for use in drinking water
  • Cardboard box containing 2 sachets of 50 g suspension for use in drinking water
  • Cardboard box containing 24 sachets of 20 g suspension for use in drinking water

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Hybrid application (Article 13(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • KRKA tovarna zdravil d.d. Novo mesto
Marketing authorisation date:
Manufacturing sites for batch release:
  • TAD Pharma GmbH
  • KRKA tovarna zdravil d.d. Novo mesto
Responsible authority:
  • Spanish Agency Of Medicines And Medical Devices
Authorisation number:
  • 2761 ESP
Date of authorisation status change:
Reference member state:
  • France
Procedure number:
  • FR/V/0242/001
Concerned member states:
  • Austria
  • Belgium
  • Bulgaria
  • Czechia
  • Denmark
  • Estonia
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Spanish (PDF)
Published on: 15/02/2024
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Spanish (PDF)
Published on: 4/06/2024
Download

Labelling

This document does not exist in this language (English). You can find it in another language below.
Spanish (PDF)
Published on: 15/02/2024
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."